To whom it may concern,

July 1, 2025

Company name: ExaWizards Inc.
Name of representative: Makoto Haruta,
Representative Director and President, CEO
(TSE Code No.4259)
Inquiries: Tomoaki Maekawa,
Executive Officer, Corporate Management
Division Manager, CFO

(Correction) Notice of Commercialization of New Medical AI App from Subsidiary

ExaWizards Inc. (hereinafter, the “Company”) hereby announces that the following amendment has been made to the content presented in the attachment of “Notice of Commercialization of New Medical AI App from Subsidiary” on July 1, 2025.

Detail of Change

The original notice has been changed on page 4.

(Before)
Marketing approval number : 13B2X10629000001

(After)
Notification number : 13B2X10629000001

(Amended)

To whom it may concern,

July 1, 2025

Company name: ExaWizards Inc.
Name of representative: Makoto Haruta,
Representative Director and President, CEO
(TSE Code No.4259)
Inquiries: Tomoaki Maekawa,
Executive Officer, Corporate Management
Division Manager, CFO

Notice of Commercialization of New Medical AI App from Subsidiary

ExaWizards Inc. (hereinafter, "the Company") is pleased to announce that at the management meeting held on June 30, 2025, the Company resolved to commercialize the AI gait analysis medical application "LocoStep," developed by ExaMD Inc., a wholly owned subsidiary of the Company.

1. Outline of the Subsidiary

(1) Name	ExaMD Inc.
(2) Headquarters	5F, Sumitomo Fudosan Mita First Building, 4-2-8 Shibaura, Minato-ku, Tokyo
(3) Title & Name of Representative	Representative Director, Koji Hazama
(4) Business Description	Planning, development, sales, and alliances (including software as a medical device) of products and services utilizing multimodal AI technology, with the aim of solving social issues related to health and medical themes such as dementia.
(5) Capital	50 million yen

2. Background leading up to commercialization

While developing various AI models for the medical and healthcare fields, the Company and ExaMD Inc. have successfully developed highly accurate models in the area of cognitive and motor functions through collaboration with medical institutions. The model is clinically useful and has potential for development as Software as a Medical Device (SaMD), and the model is expected to make a significant contribution to addressing the social issue of the super-aging society that Japan is currently facing.

3. Outline of the new product LocoStep

(1) Outline of LocoStep

LocoStep is the first in Japan that medical AI application (ML-SaMD) can measure motor function easily and quickly by taking a video of a person walking several meters with a smartphone or iPad.

Please refer to the attached press release for more information on LocoStep.

(2) Impact of LocoStep on consolidated net sales

As the aging population continues to grow, it is estimated that there are approximately 10 million patients with impaired motor function in Japan, as seen with conditions such as frailty and knee arthropathy, and this number is increasing every year. This software is intended for use by healthcare providers to broadly support patients who are at risk of declining motor function. However, the impact on sales for the current fiscal year (ending March 2026) is expected to be minimal.

(3) Expenses to be spent on the start-up of LocoStep

Development expenses consist mainly of in-house engineers and include some other subcontracting expenses.

Total development costs	Approx. 50 million yen
(Breakdown: personnel expenses)	Approx. 40 million yen
(Breakdown: subcontracting costs)	Approx. 10 million yen

4. Schedule

(1) Date of Management Meeting	June 30, 2025
(2) Launch Date	July 1, 2025 (scheduled)

5. Future Outlook

The impact of this matter on the consolidated financial results for the full fiscal year ending March 2026 is expected to be minimal. The Company currently examining the potential impact on subsequent fiscal years, and if any matters requiring disclosure arise in the future, it will promptly announce them.

(Attachment)

News Release


July 1,2025
ExaWizards Inc.
(TSE Code No.4259)
ExaMD Inc.

ExaMD, an ExaWizards Group Company, Launches LocoStep, Japan's First*1 AI Gait Analysis Application Covered by Reimbursement

－ Easy, low-cost motor function testing—set up in one day with your iPhone or iPad －

ExaMD Inc. (Minato-ku, Tokyo; Representative Director, Koji Hazama; hereafter, “ExaMD”), a group company of ExaWizards Inc. (Minato-ku, Tokyo; Representative Director and President, CEO, Makoto Haruta, hereinafter, “ExaWizards”), has developed “LocoStep,” the first AI-based gait analysis application in Japan for medical institutions and rehabilitation facilities, and launched it on July 1, 2025.

LocoStep is a Software as a Medical Device (SaMD) that uses AI to quickly quantify motor function based on patient gait videos taken with an iPhone or iPad. Since no dedicated equipment is required, there’s no need for delivery, installation, or storage, making it easy to use right away, even in limited spaces. The use of proprietary technology allows the software, including its AI components, to operate with low energy consumption, making it cost-effective operation possible.



Background of development

As Japan’s aging population continues to grow, it’s estimated that around 10 million people now live with impaired motor function, due to conditions such as frailty and knee arthropathy—and this number is increasing every year. In hospitals and rehabilitation centers, there is a growing need to efficiently assess patients’ mobility and improve the quality of care for fall prevention and post-operative

rehabilitation. However, traditional motor function assessments have required special equipment and large spaces, presenting cost and operational challenges for many facilities.
LocoStep was developed to address these challenges, with the goal of enhancing productivity for healthcare professionals and improving patient satisfaction.

Features of LocoStep

- **Simple and quick**
  Measurement takes only 10 seconds. No dedicated equipment is required, making it easy to install in medical facilities.
- **Space saving**
  Simply take a picture of the patient walking 5 meters from the front. No need for a dedicated location.
- **Medical Evidence**
  Designed based on medical evidence and can be used for clinical research and academic presentations. It also promotes clinical research.
- **Energy saving**
  Installation and operation costs can be significantly reduced.
- **High quality**
  Quality Management (QMS) in accordance with medical device development. Improved AI accuracy through joint research with Juntendo University.
- **iPhone/iPad compatible**
  No dedicated equipment is required.

Trade name	: Gait analysis tool “LocoStep”
Notification number	: 13B2X10629000001

The dedicated site is here. (In Japanese Only) https://examd.com/locomo/

Expected Results of Introduction

With the introduction of LocoStep, medical staff can easily and quickly quantify patients’ motor function in clinical settings. This is expected to streamline tasks such as rehabilitation and motor function assessments in medical institutions, allowing limited healthcare resources to be utilized more effectively. In addition, because no specialized equipment is required, LocoStep offers lower implementation and operational costs compared to conventional systems.

Furthermore, visualizing patients’ motor function—including fall risks—enables medical staff to take appropriate preventive measures in advance for events related to decreased physical function. This also helps to enhance the quality of rehabilitation and is expected to improve patient satisfaction.

Future Development

ExaMD will continue to work on building clinical evidence through collaboration with medical institutions and academic societies, as well as promoting awareness of motor function assessment. It also plans to explore new features related to motor function evaluation.

About ExaMD

ExaMD develops and provides AI technology-based products and services aimed at solving social issues in the health and medical fields. It pursues practicality in the medical field through thorough quality control in accordance with medical device development.

(Note)
*1: In-house research; survey date: June 2025; survey scope: AI-equipped medical applications for measuring motor function that can be used with smartphones.

ExaMD Company Profile

Company name	: ExaMD Inc.
Location	: 5F, Sumitomo Fudosan Mita First Building, 4-2-8 Shibaura, Minato-ku, Tokyo
Establishment	: February 2024
Representative	: Representative Director, Koji Hazama
Business	: Planning, development, sales, and alliances (including software as a medical device) of products and services utilizing multimodal AI technology, with the aim of solving social issues related to health and medical themes such as dementia.
URL	: https://examd.com/ (In Japanese Only)

ExaWizards Company Profile

Company name	: ExaWizards Inc.
Location	: 5F, Sumitomo Fudosan Mita First Building, 4-2-8 Shibaura, Minato-ku, Tokyo
Establishment	: February 2016
Representative	: Representative Director and President, CEO, Makoto Haruta
Business	: Development of AI-enabled services for industrial innovation and social problems solutions
URL	: https://exawizards.com/en/

<For public relations inquiries, please contact
ExaWizards Corporation Public Relations Email: publicrelations@exwzd.com